I am positive on NPS; I own 15,000 share with an average price of $6.50. Short sighted investors fail to realize an increasing revenue stream, increased market opportunities for Sensipar in Asia, Preos in the US, and a large unmet need with Teduglutide.
I am 90% certain Teduglutide will be approved, when it is it will cause NPS to rocket to $10 easily. If they announce a partner in two weeks, it will be heading to $5.
Hold tight, worse case senerio is a buyout for at least double the current price.
Teduglutide studies will be completed by Q3. With a 21 day study indicating "statistical significant" results, the 6 month study will undoubtedly show equally or better result. Anybody betting against this one does not understand statistics.
This is the most under appreciated biotech out there. Hold tight, you will be richly rewarded.